In the first stage of a phase III study called CLL11, the drug in combination with chemotherapy significantly reduced the risk of disease worsening or death compared to chemotherapy alone in previously untreated patients.

FORBES: Roche's Worth $58 On Continued Growth And Strong Pipeline

Many eye-vitamin formulations currently on the market are based on research conducted by the National Institutes of Health in a project called Age-Related Eye Disease Study, or AREDS. The first phase of the clinical trial, completed in 2001, found that a specific combination of vitamins C and E, along with beta-carotene and zinc, reduced the risk of age-related macular degeneration by as much as 25%.

WSJ: The Crucial Years for Protecting Your Eye Health

Thus, the Combination of Hyper connectivity, Network Theory, Emergence, are key to understanding the next phase shift in human history.

FORBES: The Great Disruption Or The Big Shift?